Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology.
Diouf M, Filleron T, Pointet AL, Dupont-Gossard AC, Malka D, Artru P, Gauthier M, Lecomte T, Aparicio T, Thirot-Bidault A, Lobry C, Fein F, Dubreuil O, Landi B, Zaanan A, Taieb J, Bonnetain F. Diouf M, et al. Among authors: pointet al. Qual Life Res. 2016 Jul;25(7):1713-23. doi: 10.1007/s11136-015-1198-x. Epub 2015 Nov 28. Qual Life Res. 2016. PMID: 26615615 Clinical Trial.
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Pointet AL, Tougeron D, Pernot S, Pozet A, Béchade D, Trouilloud I, Lourenco N, Hautefeuille V, Locher C, Williet N, Desrame J, Artru P, Soularue E, Le Roy B, Taieb J. Pointet AL, et al. Clin Res Hepatol Gastroenterol. 2020 Jun;44(3):295-301. doi: 10.1016/j.clinre.2019.08.009. Epub 2019 Oct 10. Clin Res Hepatol Gastroenterol. 2020. PMID: 31607641
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
Rinaldi Y, Pointet AL, Khemissa Akouz F, Le Malicot K, Wahiba B, Louafi S, Gratet A, Miglianico L, Laharie H, Bouhier Leporrier K, Thirot Bidault A, Texereau P, Coriat R, Terrebonne E, Gouttebel MC, Malka D, Bachet JB, Lepage C, Taieb J; PRODIGE 37 Investigators/Collaborators. Rinaldi Y, et al. Among authors: pointet al. Eur J Cancer. 2020 Sep;136:25-34. doi: 10.1016/j.ejca.2020.05.018. Epub 2020 Jul 2. Eur J Cancer. 2020. PMID: 32623182 Clinical Trial.
Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study.
d'Engremont C, Vernerey D, Pointet AL, Simone G, Fein F, Heyd B, Koch S, Vuitton L, Kim S, Jary M, Lamfichek N, Turco C, Lakkis Z, Berger A, Bonnetain F, Taieb J, Bachellier P, Borg C. d'Engremont C, et al. Among authors: pointet al. BMC Cancer. 2016 Oct 26;16(1):823. doi: 10.1186/s12885-016-2860-6. BMC Cancer. 2016. PMID: 27782813 Free PMC article.
Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study.
Williet N, Saint A, Pointet AL, Tougeron D, Pernot S, Pozet A, Bechade D, Trouilloud I, Lourenco N, Hautefeuille V, Locher C, Desrame J, Artru P, Thirot Bidault A, Le Roy B, Pezet D, Phelip JM, Taieb J. Williet N, et al. Among authors: pointet al. Therap Adv Gastroenterol. 2019 Sep 25;12:1756284819878660. doi: 10.1177/1756284819878660. eCollection 2019. Therap Adv Gastroenterol. 2019. PMID: 31598136 Free PMC article.
5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases.
Pernot S, Velut G, Kourie RH, Amouyal G, Sapoval M, Pointet AL, Landi B, Zaimi Y, Lepère C, Pellerin O, Taieb J. Pernot S, et al. Among authors: pointet al. Clin Res Hepatol Gastroenterol. 2018 Jun;42(3):255-260. doi: 10.1016/j.clinre.2017.11.004. Epub 2017 Dec 7. Clin Res Hepatol Gastroenterol. 2018. PMID: 29233520
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.
Neuzillet C, Casadei Gardini A, Brieau B, Vivaldi C, Smolenschi C, Brandi G, Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi M, Dahan L, Aprile G, Boussaha T, Malka D, Crusz SM, Le Sourd S, Meurisse A, Lièvre A, Vernerey D; AGEO (Association des Gastro-Entérologues Oncologues); GICO (Italian Group of Cholangiocarcinoma) Investigators; Gustave Roussy Institute Cohort; Barts Cancer Institute Cohort. Neuzillet C, et al. Among authors: pointet al. Eur J Cancer. 2019 Apr;111:94-106. doi: 10.1016/j.ejca.2019.01.019. Epub 2019 Mar 1. Eur J Cancer. 2019. PMID: 30826661 Free article.
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N, Tanchot C, Stockmann C, Combe P, Berger A, Zinzindohoue F, Yagita H, Tartour E, Taieb J, Terme M. Voron T, et al. Among authors: pointet al. J Exp Med. 2015 Feb 9;212(2):139-48. doi: 10.1084/jem.20140559. Epub 2015 Jan 19. J Exp Med. 2015. PMID: 25601652 Free PMC article.
13 results